Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
ANCR
Specific or universal ncRNAs
Universal ncRNAs
Class
Long noncoding RNA
Biomarker
Yes
Biomarker application
Treatment
Upstream regulatory factors
Not available
Downstream target
Not available
Cancer name
Osteosarcoma
Cancer site
qRT-PCR,Western blot
Treatment type
Chemotherapy
Drug
Adriamycin
Impact of wild-type ncRNA on chemotherapy resistance
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
SiRNA-mediated knockdown of ANCR decreased in vitro proliferation, while increasing sensitivity to Dox treatment in the KHOS-DR/U2OS-DR cells
Tissue resource
osteosarcoma doxorubicin-resistant cell lines U2OS-DR
osteosarcoma patients chemoresistant and chemosensitive to adriamycin
osteosarcoma doxorubicin-sensitive cell lines KHOS
osteosarcoma doxorubicin-sensitive cell lines U2OS
osteosarcoma doxorubicin-resistant cell lines KHOS-DR
Experiment
None
Institute
West China Hospital
Massachusetts General Hospital and Harvard Medical School
Country
China
United States
Continent
Asia
North Amercian
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.